JP2008238169A - Method for adjusting concentration of aqueous solution containing hydrate slurry-forming drug and method for supplying hydrate slurry-forming drug - Google Patents

Abstract

The present invention provides a method capable of easily adjusting an aqueous solution of a hydrate slurry-forming drug at a site where a hydrate slurry is used and also performing a supercooling release treatment easily.
In supplying a hydrate slurry-forming agent to a site for use by cooling an aqueous solution containing the hydrate slurry-forming agent and generating and utilizing the hydrate slurry, a concentrated aqueous solution of the hydrate slurry-forming agent is used. A method for supplying a hydrate slurry-generating drug, comprising: supplying to a use site, and diluting a concentrated aqueous solution of the hydrate slurry-generating drug to a predetermined concentration at the use site.
[Selection] Figure 1

Description

  The present invention relates to a method of supplying a drug that generates a slurry of hydrate (clathrate compound) to a use site.

  When an aqueous solution containing a guest compound (hydrate slurry-forming agent) such as tetra-n-butylammonium salt, tetraiso-amylammonium salt, tetraiso-butylphosphonium salt, triiso-amylsulfonium salt is cooled, the hydrate It is known that this hydrate becomes fine particles and floats in an aqueous solution to form a highly fluid hydrate slurry. Such hydrates and hydrate slurries have favorable characteristics as cold storage materials such as air-conditioning equipment or cold transport media, and there is an increasing need for the development of utilization techniques.

  However, since air conditioning equipment using an aqueous solution that generates hydrate slurry has not yet become widespread, the state of hydrate slurry generation drug suppliers to users' hydrate slurry usage sites There is no established method for transporting hydrate slurry-generating drugs and making adjustments at the site of use. For this reason, it has been difficult to obtain an aqueous solution of a hydrate slurry-forming drug having characteristics according to the design of the equipment designer. In connection with this point, for example, in the field of heat storage agents, there is a sales form in which a heat storage agent supplier manufactures a capsule containing the heat storage agent, transports it to a user's site, and fills the user's heat storage tank. It is different from being established.

  In addition, the hydrate slurry-forming drug hydrate as described above includes a first hydrate having a low hydration number and a low formation temperature, and a second hydrate having a high hydration number and a high formation temperature. In addition, the second hydrate is advantageous in that it is used as a cold storage material or a cold transport medium because it has a larger heat density and can reduce the transport power. However, when the aqueous solution containing the hydrate slurry-forming agent as described above is cooled, the first hydrate is formed from the supercooled aqueous solution or the first hydrate in the supercooled state. It is known to go through the process of forming dihydrate. For this reason, when supercooling is released after large supercooling occurs, the viscosity rapidly increases, and in the worst case, equipment such as a heat exchanger in the system may be blocked. However, as described above, a simple supercooling release treatment method has not been established under a situation where a method for adjusting an aqueous solution of a hydrate slurry-generating drug at a use site has not been established.

  An object of the present invention is to provide a method capable of easily adjusting an aqueous solution of a hydrate slurry-forming drug according to design conditions at a site where a hydrate slurry is used, and easily performing a supercooling release treatment.

  The method for supplying a hydrate slurry-generating drug according to the present invention supplies a concentrated aqueous solution of a hydrate slurry-generating drug to a use site, and dilutes the concentrated aqueous solution of the hydrate slurry-generating drug at the use site to obtain a predetermined concentration. It is characterized by doing.

  Here, the predetermined concentration corresponds to the heat density, transport heat amount, and transport power efficiency as the heat storage agent or the cold transport medium required at the use site. In the present invention, the hydrate slurry-generating drug is strictly a hydrate-forming drug, but any drug that generates hydrate slurry as a result is sufficient. In addition, the concentrated aqueous solution in the present invention means an aqueous solution in which a solute is present at a relatively high concentration with respect to the solvent, and an aqueous solution that is realized by increasing the relative amount of the solute with respect to the solvent by increasing the solute mass. It is realized by removing the solvent from the initial aqueous solution, the aqueous solution realized by adding the solute to the original aqueous solution, the aqueous solution realized by increasing the relative amount of solute with respect to the solvent by reducing the amount of solvent Any aqueous solution.

  In the present invention, it is preferable to dilute the concentrated aqueous solution of the hydrate slurry-generating drug at the use site and to mix fine particles as a supercooling release agent.

  In the present invention, it is most convenient to dilute the concentrated aqueous solution with tap water containing a sufficient amount of fine particles (for example, kaolin) that acts as a supercooling release agent. Needless to say, appropriate fine particles serving as a supercooling release agent may be added separately.

  In the present invention, it is preferable to dilute the concentrated aqueous solution while measuring the concentration of the hydrate slurry-forming drug in the aqueous solution using a refractometer or an electric conductivity meter.

  In this invention, in order to produce | generate the 2nd hydrate with a high heat storage density in utilization temperature range (for example, 5-12 degreeC), the density | concentration of the hydrate slurry production | generation chemical | medical agent in aqueous solution shall be 18% or less. It is preferred to dilute the concentrated aqueous solution. This makes it possible to produce a second hydrate having a higher heat retention or heat storage density than the first hydrate. In the present invention, “%” means “% by weight”.

  In the present invention, it is preferable to mix a surfactant when diluting the concentrated aqueous solution of the hydrate slurry-generating drug so that the conveyance power of the aqueous solution can be reduced.

  In the present invention, it is preferable to prevent corrosion of equipment in the system by mixing an anticorrosive agent when diluting the concentrated aqueous solution of the hydrate slurry-generating drug.

  In addition, a supercooling release agent and, if necessary, a surfactant and / or an anticorrosive agent may be added to the concentrated aqueous solution in advance, or a supercooling release agent and, if necessary, a surfactant and / or an anticorrosive agent. The concentrated aqueous solution may be diluted with water to which is added. When these methods can adjust the concentrations of the supercooling release agent, the surfactant, and the anticorrosive agent to desired values, no further fine adjustment is necessary.

  In addition, after diluting the concentrated aqueous solution with water, an amount of supercooling release agent corresponding to the additional amount of water and, if necessary, a surfactant and / or an anticorrosive agent are added to bring these concentrations to the desired values. Fine adjustments may be made so that

  Further, the concentration of the concentrated aqueous solution of the hydrate slurry-generating drug is adjusted to 30%, for example. The concentration of the concentrated aqueous solution of the hydrate slurry-generating drug may be adjusted to 40%. The concentration of the concentrated aqueous solution of the hydrate slurry-generating drug may be adjusted to 40% or more.

  In another method for supplying a hydrate slurry-forming drug according to the present invention, when supplying a drug for generating a hydrate slurry to a hydrate slurry utilization site, water is supplied from a concentrated aqueous solution of the hydrate slurry-forming drug. The hydrate slurry-generating drug powder produced by evaporation is supplied to a use site, and the hydrate slurry-generating drug powder is dissolved in water at the use site to obtain an aqueous solution having a predetermined concentration.

  In addition, it is preferable that the aqueous solution has a predetermined concentration and fine particles are mixed as a supercooling release agent.

  Even in this method, it is simplest to dissolve the powder of the hydrate slurry-generating drug using tap water containing fine particles that act as a supercooling release agent.

  In addition, it is preferable to dissolve the powder of the hydrate slurry-forming drug while measuring the concentration of the hydrate slurry-forming drug in the aqueous solution using a refractometer or an electric conductivity meter.

  In addition, it is preferable to dissolve the hydrate slurry-forming drug powder so that the concentration of the hydrate slurry-generating drug in the aqueous solution is 18% or less.

  In addition, it is preferable to mix at least one of a surfactant and an anticorrosive when the hydrate slurry-forming drug powder is dissolved.

  Further, the hydrate slurry-forming drug powder may be dissolved using water to which at least one of a supercooling release agent, a surfactant, and an anticorrosive agent is added.

  According to another aspect of the present invention, there is provided a method for supplying a hydrate slurry-forming drug, wherein the hydrate slurry has a concentration that gives a harmonious melting point of the hydrate when the hydrate slurry-forming drug is supplied to a site where the hydrate slurry is used. A feature of the present invention is to supply an aqueous solution of a hydrate slurry-forming agent at a concentration or higher that gives a harmonic melting point of an aqueous solution or hydrate of the slurry-forming agent to a use site, and dilute the aqueous solution of the hydrate slurry-forming agent at the use site. And

  According to another aspect of the present invention, there is provided a method for supplying a hydrate slurry-forming drug, wherein the hydrate slurry has a concentration that gives a harmonious melting point of the hydrate when the hydrate slurry-forming drug is supplied to a site where the hydrate slurry is used. Concentration adjustment is performed on an aqueous solution of a hydrate slurry-forming agent at a concentration or higher that gives a harmonic melting point of the aqueous solution or hydrate of the slurry-forming agent to prepare an aqueous solution of the hydrate slurry-forming agent having a desired concentration. It supplies to a use site, and dilutes the aqueous solution of the said hydrate slurry production | generation chemical | medical agent in a use site.

  According to the present invention, it is possible to easily adjust the aqueous solution of the hydrate slurry-forming drug at the site where the hydrate slurry is used and to easily perform the supercooling release treatment.

  In the present invention, as described above, the concentrated aqueous solution of the hydrate slurry-generating drug is transported to the use site, and the concentrated aqueous solution of the hydrate slurry-generating drug is diluted at the use site and mixed with fine particles as a supercooling release agent. To do.

A method for producing a concentrated aqueous solution of a hydrate slurry-generating drug will be described.
Create a concentrated aqueous solution just by dissolving the industrially produced hydrate slurry-generating drug powder in water, or add water to an industrially manufactured highly concentrated aqueous solution to prepare a concentrated aqueous solution. When the hydrate slurry-forming drug is supplied, impurities other than the hydrate slurry-forming drug may be contained in the hydrate slurry-forming drug powder or highly concentrated aqueous solution manufacturing process. Therefore, there is a concern that problems such as discoloration and odor may occur when used as a regenerator or a cold transport medium for air conditioning equipment. The same problem occurs when using a powder having a low purity of the hydrate slurry-forming drug. Therefore, it is preferable to perform a treatment for removing impurities other than the hydrate slurry-forming drug contained in the powder of the hydrate slurry-forming drug.

  Tetra-n-butylammonium bromide using a method for producing a concentrated aqueous solution having a hydrate slurry-forming drug concentration of 30%, 40%, or 40% or more as a hydrate slurry-forming drug (guest compound) A case where (TBAB) is used will be described.

(1) Method of preparing a concentrated aqueous solution having a concentration of 30% A raw aqueous solution having a concentration of 18% or less of a hydrate slurry-forming drug powder in water is loaded in a concentration container having a cooling device and a heating device. The raw aqueous solution is cooled to produce hydrate crystals. At this concentration, a second hydrate is formed. The low-concentration residual aqueous solution is discharged from the concentration container, and the hydrate remaining as a solid is heated to melt the hydrate to obtain a concentrated concentrated aqueous solution. Impurities contained in the hydrate slurry-forming drug powder remain in the remaining aqueous solution and are removed from the concentrated aqueous solution.

  The concentration of the concentrated aqueous solution is about 33% when calculated from the ratio of the wettable powder constituting the second hydrate and the water molecules, but it is actually about 30%. This is probably because a small amount of water remains around the hydrate crystal mass. Moreover, it is preferable to cool at the temperature or cooling rate which produces | generates a 2nd hydrate selectively.

  In place of the above operation, a raw aqueous solution in which the powder of the hydrate slurry forming drug is dissolved in water is put in a container, a cooling pipe is put in the container and cooled at a temperature of 8 ° C. or less, and a hydrate is formed on the outer surface of the cooling pipe. If the hydrate adheres, place the cooling tube with hydrate in another empty container, pour warm water into the cooling tube, dissolve the adhered hydrate, and create a concentrated aqueous solution that does not contain impurities. Also good. By this operation, a second hydrate is produced, and a concentrated aqueous solution having a concentration of 30% can be produced.

(2) Method for preparing a concentrated aqueous solution having a concentration of 40% High concentration of a raw aqueous solution having a concentration of 18% or more of a hydrate slurry-forming drug powder in water or an industrially produced hydrate slurry-forming drug The aqueous solution is charged into a concentration container having a cooling device and a heating device, and the raw aqueous solution or the highly concentrated aqueous solution is cooled to produce hydrate crystals. At this concentration, a first hydrate is formed. The low-concentration residual aqueous solution is discharged from the concentration vessel, and the hydrate remaining as a solid is heated to melt the hydrate to obtain a concentrated aqueous solution. Impurities contained in the hydrate slurry-forming drug powder remain in the remaining aqueous solution and are removed from the concentrated aqueous solution.

  The concentration of this concentrated aqueous solution is about 41% when calculated from the ratio of the wettable powder constituting the first hydrate to the water molecules, but it is actually about 40%. This is probably because a small amount of water remains around the hydrate crystal mass. Moreover, it is preferable to cool at 8 ° C. or higher, which is a temperature for selectively producing the first hydrate, or at a cooling rate. Alternatively, a concentrated aqueous solution with a concentration of 40% may be prepared by the above operation using the concentrated aqueous solution with a concentration of 30% prepared by the method (1).

  In place of the above operation, a raw aqueous solution obtained by dissolving a hydrate slurry-forming drug powder in water is put in a container, a cooling pipe is put in the container and cooled at a temperature of 8 ° C. or more, and a hydrate is formed on the outer surface of the cooling pipe. If the hydrate adheres, place the cooling tube with hydrate in another empty container, pour warm water into the cooling tube, dissolve the adhered hydrate, and create a concentrated aqueous solution that does not contain impurities. Also good. By this operation, the first hydrate is produced and a concentrated aqueous solution having a concentration of 40% can be produced.

  The TBAB physical property value of “about 41%” quoted in the method of preparing a concentrated aqueous solution having a concentration of 40% when TBAB is used as the hydrate slurry-generating agent is more precisely 40.6% by weight. . When broadly defined for a hydrate slurry-forming drug, this concentration means "concentration that gives a harmonic melting point when the hydrate slurry-forming drug is dissolved in water" (referred to as the harmonic melting point concentration). At the harmonic melting point concentration, the concentration of the hydrate forming drug in the hydrate is equal to the concentration of the hydrate forming drug in the aqueous solution. The process specifically described for preparing a concentrated aqueous solution of TBAB having a concentration of 40% can be achieved by replacing the content specific to TBAB with the content specific to each hydrate slurry-generating agent corresponding thereto. It can be widely applied to produce an aqueous solution having a concentration that gives a harmonic melting point when the slurry-forming agent is dissolved in water. In the process specifically described for producing a concentrated aqueous solution of TBAB having a concentration of 40%, it is not always possible to accurately achieve about 41% (about 40.6%) as the theoretical value of the harmonic melting point concentration. The present invention aims at a concentration close to the theoretical value of the harmonic melting point concentration of the hydrate slurry-forming agent or a value of the theoretical harmonic melting point concentration, but as a result, the theoretical harmonic melting point concentration inevitably Concentration deviating from the value of the theoretical harmonic melting point concentration, which is realized by deviating from the value of the value, is also the “concentration that gives the harmonic melting point when the hydrate slurry-forming agent is dissolved in water” (harmonic melting point concentration) I will call it.

  The aqueous solution having a concentration that gives a harmonic melting point when the hydrate slurry-forming agent is dissolved in water, which is produced as described above, is exactly the concentration that gives the inherent harmonic melting point of the hydrate slurry-forming agent. For example, in the case of TBAB, the density value is constant, such as about 40%. This means that the work of setting the target concentration value is facilitated when the aqueous solution is directly carried out or supplied as a concentrated aqueous solution to the use site and diluted at the use site. This is because the concentration is already known if the concentrated aqueous solution is taken out. In addition, when it is necessary to adjust the concentration of the concentrated aqueous solution in advance before the concentrated aqueous solution is carried out or supplied to the use site, a desired amount of the hydrate slurry-generating agent is determined for a certain amount of the concentrated aqueous solution. This means that the operation of setting the target concentration value is facilitated by adding water or adding a desired amount of water. This is because the concentration is already known if the concentrated aqueous solution is taken out. Therefore, an aqueous solution having a concentration that gives a harmonic melting point when the hydrate slurry-forming drug is dissolved in water is used as a concentrated aqueous solution, or the concentration is further adjusted with reference to the concentrated aqueous solution, and a desired concentration value is set. It can be said that there are special technical features and advantages as a method for supplying a hydrate slurry-generating drug to be carried out or supplied to a use site and used.

(3) Method for producing concentrated aqueous solution having a concentration of 40% or more Concentrated aqueous solution having a concentration of 30% produced by the method of (1) or the concentrated aqueous solution of 40% concentration produced by the method of (2) The container is charged and the concentrated aqueous solution is heated to evaporate the water in the aqueous solution and concentrate to obtain a concentrated aqueous solution having a concentration of 40% or more. Impurities contained in the powder of the hydrate slurry-forming drug are removed by the operation (1) or (2).

  Moreover, the effect which becomes easy to produce | generate a hydrate is also brought about by using the aqueous solution which once produced | generated the hydrate like the method of (1) (2) (3) as a concentrated aqueous solution for preparation at a utilization site. .

  A concentrated aqueous solution having a concentration of a hydrate slurry-generating agent of 30%, 40%, or 40% or more is supplied from the supplier to the user's use site. By diluting the concentrated aqueous solution so as to obtain an optimum concentration of 18% or less, an aqueous solution having desired characteristics can be easily prepared.

  Further, the supercooling release agent used in the present invention is a fine particle having a function of releasing (preventing) supercooling as a nucleation particle nucleation particle, and having a particle size of 10 μm so as to disperse and float in an aqueous solution. The following is preferable. If the concentration of the fine particles having a particle size of 10 μm or less in the aqueous solution is 0.1 mg / L or more, a hydrate can be efficiently produced, which is effective in preventing overcooling.

  Here, turbidity is used as one of the standards of tap water or industrial water, and 1 degree of turbidity is defined as 1 mg / L in kaolin concentration. Kaolin floats in the form of fine particles in tap water or industrial water and acts as a supercooling release agent. Turbidity is about 1 degree for general tap water (Kaolin 1 mg / L) and about 20 degrees for industrial water (Kaolin 20 mg / L). Therefore, the supercooling release agent is added only by using tap water or industrial water as water for diluting the aqueous solution containing the guest compound. The upper limit of the concentration of the supercooling release agent composed of fine particles having a particle size of 10 μm or less in the aqueous solution is about 100 mg / L. If a large amount of fine particles are dispersed and suspended above the upper limit concentration, adverse effects such as deterioration of the heat transfer performance of the heat exchanger in the system occur.

  Hereinafter, the present invention will be described in more detail with reference to the drawings. FIG. 1 is a flowchart for explaining an example of a method for supplying a hydrate slurry-generating drug according to the present invention. In this example, a case where tetra-n-butylammonium bromide (TBAB) is used as a hydrate slurry-forming agent (guest compound) will be described.

  The supplier puts the concentrated aqueous solution with a TBAB concentration of 30%, 40%, 40% or more into a tank lorry or container and transports it to the user's usage site (S1), and the user sends the concentrated aqueous solution at the usage site. The treatment is started (S2).

  The concentrated aqueous solution may or may not have been added with the supercooling release agent in advance, and the process is changed accordingly (S3). When the supercooling release agent is not added to the concentrated aqueous solution, the supercooling can be released by mixing fine particles (S4). When the supercooling release agent is added to the concentrated aqueous solution in advance, the concentrated aqueous solution is diluted with tap water as it is to obtain an aqueous solution having a TBAB concentration of 18% or less. During this time, the TBAB concentration in the aqueous solution is monitored using, for example, a refractometer. If an aqueous solution having a TBAB concentration of 18% or less is used, a second hydrate having a high heat density can be obtained when producing a hydrate slurry, and the conveyance power can be reduced (S5). In addition, when the amount of fine particles (kaolin or the like) sufficient to release the supercooling is contained in the tap water, it is not necessary to separately perform the treatment (S4) for mixing the fine particles.

  Next, a surfactant is mixed in the aqueous solution as necessary. When the surfactant is mixed, the conveyance power can be reduced when used as a warm aqueous solution (S6). Furthermore, an anticorrosive agent is mixed in the aqueous solution as necessary. When the anticorrosive is mixed, corrosion of equipment such as a heat exchanger constituting the system can be reduced (S7). Thus, preparation of the TBAB aqueous solution is completed (S8).

  In addition, the order of each process of fine particle mixing (S4), aqueous solution density | concentration adjustment (S5), surfactant (S6), and anticorrosive addition (S7) is not specifically limited. In addition, at least one of a supercooling release agent, a surfactant and an anticorrosive agent may be added in advance to the concentrated aqueous solution. In this case, the addition amount of the supercooling release agent, the surfactant, and the anticorrosive agent added in advance may be finely adjusted according to the amount of additional water at the use site.

  Further, a concentrated aqueous solution having a TBAB concentration of 50% or more, for example, 52 to 53% may be diluted.

  By using the method as described above, an aqueous solution according to the design of the facility designer can be obtained at the use site, and the system can be easily operated simply by purchasing a concentrated aqueous solution.

  In addition, when supplying the hydrate slurry to the site where the hydrate slurry is used, the powder of the hydrate slurry-generating drug produced by evaporating water from the concentrated aqueous solution of the hydrate slurry-generating drug is used. It may be supplied to the site, and the hydrate slurry-forming drug powder may be dissolved in water at the use site, and fine particles may be mixed as a supercooling release agent. Further, the same treatment as that of the concentrated aqueous solution may be performed.

  Furthermore, the powder of the hydrate slurry-generating drug prepared by evaporating water from the concentrated aqueous solution of the hydrate slurry-generating drug was supplied to the use site, and the concentrated aqueous solution was prepared. When an operation of producing a hydrate by cooling to a temperature and heating and melting it is performed, it becomes easier to produce a hydrate from an aqueous solution.

  The powder of the hydrate slurry-forming drug prepared by evaporating water from the concentrated aqueous solution having a concentration of 30%, 40%, or 40% or more of the above-mentioned hydrate slurry-forming drug is a hydrate slurry. Since it contains no impurities other than the generated chemicals, it does not cause problems such as discoloration or odor when used as a regenerator or cold transport medium for air conditioning equipment, and it does not discolor or change quality during storage. It can be stored stably. Moreover, it is also easy to carry to a utilization site, and a transportation cost can be reduced.

The flowchart figure which shows the supply method of the hydrate slurry production | generation chemical | medical agent which concerns on one Embodiment of this invention.

The present invention relates to a method for adjusting the concentration of an aqueous solution containing a hydrate slurry-forming agent that is cooled at a use site to produce a hydrate slurry, and a slurry of hydrate (clathrate compound) to the use site. The present invention relates to a method of supplying a drug that generates

Claims (20)

  Supplying the concentrated aqueous solution of the hydrate slurry-forming agent to the user site when supplying the hydrate slurry-producing agent to the user site where the aqueous solution containing the hydrate slurry-generating agent is cooled to generate and use the hydrate slurry A method for supplying a hydrate slurry-generating drug, comprising diluting a concentrated aqueous solution of the hydrate slurry-generating drug at a use site to a predetermined concentration.   Supplying the concentrated aqueous solution of the hydrate slurry-forming agent to the user site when supplying the hydrate slurry-producing agent to the user site where the aqueous solution containing the hydrate slurry-generating agent is cooled to generate and use the hydrate slurry A method for supplying a hydrate slurry-generating drug, comprising diluting a concentrated aqueous solution of the hydrate slurry-generating drug at a use site and mixing fine particles as a supercooling release agent.   Supplying the concentrated aqueous solution of the hydrate slurry-forming agent to the user site when supplying the hydrate slurry-producing agent to the user site where the aqueous solution containing the hydrate slurry-generating agent is cooled to generate and use the hydrate slurry And a method for supplying a hydrate slurry-generating drug, comprising diluting a concentrated aqueous solution of the hydrate slurry-generating drug with tap water or industrial water at a use site.   When supplying the hydrate slurry-forming agent to the site where the aqueous solution containing the hydrate slurry-forming agent is cooled to produce and use the hydrate slurry, the hydrate slurry has a concentration that gives the harmonic melting point of the hydrate. An aqueous solution of a hydrate slurry or an aqueous solution of a hydrate slurry-forming agent having a concentration or higher that gives a harmonic melting point of the hydrate is supplied to a use site, and the aqueous solution of the hydrate slurry-forming agent is diluted at the use site. A method for supplying a hydrate slurry-generating drug.   When supplying the hydrate slurry-forming agent to the site where the aqueous solution containing the hydrate slurry-forming agent is cooled to produce and use the hydrate slurry, the hydrate slurry has a concentration that gives the harmonic melting point of the hydrate. Make an aqueous solution of the hydrate slurry-forming drug of the desired concentration by adjusting the concentration of the aqueous solution of the hydrate slurry-forming drug at a concentration that gives the harmonic melting point or higher of the aqueous solution of the generated drug or the hydrate. A method for supplying a hydrate slurry-forming drug, comprising: supplying to a site, and diluting an aqueous solution of the hydrate slurry-generating drug at a use site.   The hydrate slurry-forming drug according to any one of claims 1 to 3, wherein at least one of a surfactant and an anticorrosive is mixed when diluting the concentrated aqueous solution of the hydrate slurry-generating drug. Supply method.   4. The hydrate slurry-producing agent according to claim 1, wherein at least one of a supercooling release agent, a surfactant, and an anticorrosive agent is added in advance to the concentrated aqueous solution. Supply method.   The hydrate slurry according to any one of claims 1 to 3, wherein the concentrated aqueous solution is diluted with water to which at least one of a supercooling release agent, a surfactant and an anticorrosive agent is added. Method for supplying the produced drug.   8. The water according to claim 7, wherein after the concentrated aqueous solution is diluted with water, at least one of a supercooling release agent, a surfactant, and an anticorrosive agent corresponding to the additional amount of water is added. A method for supplying a Japanese slurry producing chemical.   At the time of diluting the aqueous solution of the hydrate slurry-forming agent at a concentration that gives the harmonic melting point or the aqueous solution of the hydrate slurry-forming agent at a concentration that gives the harmonic melting point or more at the use site, at least one of a surfactant and an anticorrosive agent The method for supplying a hydrate slurry-producing drug according to claim 4, wherein one of them is mixed.   At least one of a supercooling release agent, a surfactant, and an anticorrosive agent is added to the aqueous solution of the hydrate slurry-forming agent at a concentration that gives the harmonic melting point or the aqueous solution of the hydrate slurry-forming agent at a concentration that gives the harmonic melting point or higher. The method for supplying a hydrate slurry-generating drug according to claim 4, wherein:   Using water to which at least one of a supercooling release agent, a surfactant, and an anticorrosive agent is added, an aqueous solution of a hydrate slurry-forming agent at a concentration that gives the harmonic melting point at the use site or a concentration that gives the harmonic melting point or higher The method for supplying a hydrate slurry-forming drug according to claim 4, wherein an aqueous solution of the hydrate slurry-forming drug is diluted.   The hydrate slurry according to claim 5, wherein at least one of a surfactant and an anticorrosive agent is mixed when diluting the aqueous solution of the hydrate slurry producing agent having a desired concentration at a use site. Method for supplying the produced drug.   The hydration according to claim 5, wherein at least one of a supercooling release agent, a surfactant, and an anticorrosive agent is previously added to the aqueous solution of the hydrate slurry-forming agent having a desired concentration. A method for supplying a product slurry-generating chemical.   The aqueous solution of the hydrate slurry-forming agent having a desired concentration is diluted at a use site with water to which at least one of a supercooling release agent, a surfactant, and an anticorrosive agent is added. 5. A method for supplying a hydrate slurry-producing drug according to 5.   Supplying the powder of hydrate slurry-forming drug to the use site when cooling the aqueous solution containing the hydrate slurry-forming drug and supplying the hydrate slurry-forming drug to the use site that generates and uses the hydrate slurry And a method for supplying a hydrate slurry-generating drug, wherein the powder is dissolved in water at a use site to obtain an aqueous solution having a predetermined concentration.   When supplying an agent that generates hydrate slurry to a use site that cools an aqueous solution containing the hydrate slurry-forming agent and generates and uses a hydrate slurry, the hydrate slurry-generating agent powder is used at the use site. A method for supplying a hydrate slurry-generating drug, comprising dissolving the powder of the hydrate slurry-generating drug in water at a use site and mixing fine particles as a supercooling release agent.   When the aqueous solution containing the hydrate slurry-forming agent is cooled and the hydrate slurry is generated and supplied to the use site, the hydrate slurry is supplied from the concentrated aqueous solution of the hydrate slurry-forming agent to the water. The water is characterized in that the hydrate slurry-generating drug powder produced by evaporating the water is supplied to the use site, and the hydrate slurry-generating drug powder is dissolved at the use site using tap water or industrial water. A method for supplying a Japanese slurry producing chemical.   The hydrate according to any one of claims 16 to 18, wherein at least one of a surfactant and an anticorrosive is mixed when the powder of the hydrate slurry-forming drug is dissolved at the use site. A method for supplying a slurry-generating drug.   19. The powder of the hydrate slurry-forming agent is dissolved at a use site using water to which at least one of a supercooling release agent, a surfactant and an anticorrosive agent is added. A method for supplying a hydrate slurry-producing agent according to any one of the above.

Images